levers semaglutide Retatrutide, a triple agonist, delivered 30.3% weight loss at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% of body weight) → The side effects of GLP-1s

For example, Ozempic, first approved in 2017 for type 2 diabetes, was so effective at reducing weight that it was approved specifically for obesity under the name Wegovy in 2021

Hefny A, Fikry AA, Zahran MH, Shendi AM

GLP-1 medications don't just slow stomach emptying and suppress appetite

It is composed of three essential amino acids: cysteine, glycine, and glutamic acid

The recent cardiovascular safety storm has nothing to do with it

Lilly's triple agonist retatrutide demonstrated significant A1C and weight reductions in Phase 3 type 2 diabetes trial Eli Lilly and Company Phase 3 programme The evidence base, in numbers Phase 3 trials registered 14 Completed 5 Results disclosed by Lilly 5 Peer-reviewed publications 1 Four of the five disclosed readouts are topline results reported by Lilly and have not yet been fully evaluated in a peer-reviewed publication